[
  {
    "ts": "2025-08-25T17:59:39+00:00",
    "headline": "FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles",
    "summary": "The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana. In 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition was part of a larger deal where Novo Holdings acquired Catalent, Inc. (NYSE:CTLT). The three sites, located in A",
    "url": "https://finance.yahoo.com/news/fda-flags-alarming-contamination-novo-175939597.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "6ef93961-31a5-3ea3-99a9-01419570d82e",
      "content": {
        "id": "6ef93961-31a5-3ea3-99a9-01419570d82e",
        "contentType": "STORY",
        "title": "FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles",
        "description": "",
        "summary": "The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana. In 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition was part of a larger deal where Novo Holdings acquired Catalent, Inc. (NYSE:CTLT). The three sites, located in A",
        "pubDate": "2025-08-25T17:59:39Z",
        "displayTime": "2025-08-25T17:59:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/96bda9bd2155c548b69b831d7fbc0674",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aBqwnmk.ZPBiEWz_oZm1nQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/96bda9bd2155c548b69b831d7fbc0674.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zH3osc4WSdZPDYLXEzq3Sg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/96bda9bd2155c548b69b831d7fbc0674.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-flags-alarming-contamination-novo-175939597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-flags-alarming-contamination-novo-175939597.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-25T12:00:00+00:00",
    "headline": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
    "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports",
    "url": "https://finance.yahoo.com/news/immuneering-announces-clinical-supply-agreement-120000472.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ceac4004-3ed6-3c32-b5d6-d3a1e3a85922",
      "content": {
        "id": "ceac4004-3ed6-3c32-b5d6-d3a1e3a85922",
        "contentType": "STORY",
        "title": "Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib",
        "description": "",
        "summary": "- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports",
        "pubDate": "2025-08-25T12:00:00Z",
        "displayTime": "2025-08-25T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c5aade0bb2afc0d11d8155eb3fc21e20",
          "originalWidth": 3300,
          "originalHeight": 813,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/53tFklDd5UAFRyTp2H5XyA--~B/aD04MTM7dz0zMzAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c5aade0bb2afc0d11d8155eb3fc21e20.cf.webp",
              "width": 3300,
              "height": 813,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pjW.u4fgvs4siixDdWq0xA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c5aade0bb2afc0d11d8155eb3fc21e20.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immuneering-announces-clinical-supply-agreement-120000472.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immuneering-announces-clinical-supply-agreement-120000472.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IMRX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]